Literature DB >> 10879747

Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta.

L Juillerat-Jeanneret1, S Lohm, M F Hamou, F Pinet.   

Abstract

Angiotensin peptides are potent vasoconstrictors, cell growth factors, and neuromodulators in normal and pathological situations. To assess the potential role of the angiotensins in brain tumor-associated vessels, the expression of the enzymes of the angiotensin cascade were evaluated in these tumors. The production of these bioactive peptides is dependent on the activities of exopeptidases, including several aminopeptidases and carboxypeptidases, producing angiotensin (Ang) I, II, III, IV and Ang 1-7. Human cerebral parenchymal and glioblastoma cells expressed renin, and tumor vasculature, but not glioblastoma cells, expressed angiotensin-converting enzyme. High aminopeptidase A (APA) activity, but no aminopeptidase N/B activity, was observed in human brain tumor vasculature, suggesting a predominant production of Ang III. Grafting of rat glioma cells in rat brains yielded tumors with high APA and low aminopeptidase N/B activities in tumor vessels, confirming human results. Tumor growth and APA activity in tumor vessels were not affected by chronic angiotensin-converting enzyme inhibition. The brain-derived EC219 endothelial cells expressed high APA activity, which was not involved in endothelial cell proliferation, but was down-regulated by exposure of cells to transforming growth factor-beta (TGF beta) or to TGF beta-secreting tumor cells, suggesting a role for this peptide in the control of APA activity in cerebral vasculature. Thus, APA is a potential marker of chronic dysfunction, involving loss of TGF beta function, of the metabolic blood-brain barrier, but not of neovascularization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879747     DOI: 10.1038/labinvest.3780100

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Computational tools for the interactive exploration of proteomic and structural data.

Authors:  John H Morris; Elaine C Meng; Thomas E Ferrin
Journal:  Mol Cell Proteomics       Date:  2010-06-04       Impact factor: 5.911

Review 2.  Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.

Authors:  Raluca Ioana Teleanu; Manuela Daniela Preda; Adelina-Gabriela Niculescu; Oana Vladâcenco; Crina Ioana Radu; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Pharmaceutics       Date:  2022-05-04       Impact factor: 6.525

Review 3.  Renin angiotensin system and its role in biomarkers and treatment in gliomas.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Liliana Gómez-Flores-Ramos; Montserrat Lara-Velazquez; Cordelia Orillac; Juan Luis Gómez-Amador; Talia Wegman-Ostrosky
Journal:  J Neurooncol       Date:  2018-02-16       Impact factor: 4.130

4.  Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma.

Authors:  L Juillerat-Jeanneret; J Celerier; C Chapuis Bernasconi; G Nguyen; W Wostl; H P Maerki; R-C Janzer; P Corvol; J-M Gasc
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

5.  Derivatives of 5-aminolevulinic Acid for photodynamic therapy.

Authors:  Ryan F Donnelly; Paul A McCarron; A David Woolfson
Journal:  Perspect Medicin Chem       Date:  2007-12-11

6.  Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System.

Authors:  María Jesús Ramírez-Expósito; José Manuel Martínez-Martos
Journal:  Biomedicines       Date:  2018-01-26

7.  Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury.

Authors:  Jean-Christophe Wyss; Rajesh Kumar; Josip Mikulic; Manfred Schneider; Jean-Luc Mary; Johannes D Aebi; Lucienne Juillerat-Jeanneret; Dela Golshayan
Journal:  Front Pharmacol       Date:  2019-11-08       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.